Drug class
Neonatal Fc receptor (FcRn) blocker; fully human IgG1 monoclonal antibody
Mechanism of action
Binds FcRn and prevents recycling of IgG, increasing lysosomal degradation and lowering circulating IgG concentrations, including pathogenic autoantibodies.
General use cases
- Treatment of generalized myasthenia gravis in adults and paediatric patients aged 12 years and older who are anti-AChR or anti-MuSK antibody positive
- Treatment of warm autoimmune haemolytic anaemia in adults and paediatric patients aged 12 years and older currently or previously treated with corticosteroids under the US IMAAVY indication (2026 label update)
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
